UPMC Enterprises

Cerevance LLC is engaged in the development of therapeutics targeting specific proteins expressed selectively in brain cell types affected by neurological diseases. The company utilizes its proprietary NETSseq platform to profile distinct brain cell types, such as neurons and glial cells, in mature human brain tissue. This technology reveals transcriptional and epigenetic differences, facilitating the early detection and treatment of serious neurological and psychiatric disorders, including Alzheimer’s and Parkinson’s diseases. Founded in 2016, Cerevance is headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom. The company's focus is on advancing new medicines for central nervous system diseases by addressing the underlying mechanisms of neurodegeneration and related conditions.

We’re building consumer health businesses that improve access and elevate patient experience. We partner with entrepreneurs to identify, launch, and scale new businesses. Redesign companies are powered by a growing ecosystem of ideas, capital, talent, and partners, and benefit from our singular focus on consumer health.

Moxe Health Corporation develops a clinical data clearinghouse that enables the efficient bi-directional exchange of clinical, analytic, and administrative data among health systems, health plans, and healthcare technology vendors. The company offers solutions that automate chart retrieval and the release of information, transitioning health systems from manual processes to a fully electronic, auditable method of record management. Moxe’s platform facilitates access to essential data for risk adjustment, quality improvement, and care management programs, supporting health plans and providers in the shift to value-based care. Through its Substrate integration platform and Convergence framework, Moxe ensures that relevant patient information is integrated directly into clinician workflows within electronic medical records. Founded in 2012 and based in Madison, Wisconsin, Moxe Health aims to enhance the connectivity and functionality of existing healthcare data systems while maintaining compliance with HIPAA regulations.

Hashed Health is a healthcare innovation firm based in Nashville, Tennessee, established in 2016. The company specializes in leveraging blockchain and distributed ledger technologies to create solutions for various challenges in the healthcare sector. It offers a range of services, including product management, regulatory guidance, and technology support, aimed at fostering an ecosystem for collaborative enterprises. Hashed Health focuses on building networks that facilitate the secure exchange of clinical, financial, and business data, while also addressing issues such as multi-party business process automation and data custody. By partnering with healthcare and life sciences organizations, the firm aims to develop new business models and drive innovation through collaboration, ultimately enhancing the efficiency and effectiveness of healthcare delivery.

BrainCheck, Inc. specializes in cognitive health solutions aimed at healthcare and athletic organizations in the United States. Founded in 2013 and based in Houston, Texas, the company offers BrainCheck, a mobile interactive screening tool available on iOS and Android devices. This tool enables users to monitor their cognitive health, particularly concerning issues like concussions and memory changes, by tracking performance over time and comparing results with general population data. The development of BrainCheck is grounded in two decades of research from the Eagleman Laboratory for Perception and Action at Baylor College of Medicine, led by Dr. David Eagleman. The platform encourages users to engage in meaningful discussions with their clinicians regarding their cognitive health, thereby facilitating informed decision-making. Through its innovative approach, BrainCheck aims to enhance understanding of brain function and empower individuals with actionable data.

Ring Therapeutics, Inc. is a biotechnology company that specializes in developing gene therapies through its innovative viral vector platform, Anellovector. This platform leverages the human commensal virome to create redosable and targetable DNA therapies, addressing key limitations of existing gene and DNA treatments, such as restricted access to diverse tissues and challenges with tolerability and genomic integration. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics aims to expand the scope of gene therapy beyond traditional gene replacement, enabling a broader range of applications across various medical fields, including genetic disorders, ophthalmology, oncology, and metabolic diseases. By focusing on cellular and tissue specificity, the company aspires to unlock new therapeutic possibilities for previously inaccessible conditions.

Sempre Health, Inc. owns and operates a platform and offers behavior-based healthcare pricing to healthcare industry. The company works with health plans and pharmaceutical manufacturers to dynamically adjust a patient's co-payment based on individual adherence and behavior. It parses prescription records to predict the right price based on the patient's adherence to taking medicines in time. The company provides the patients access to their current discounts, why they got those discounts, and guidance on how to improve their health, via SMS. The company was founded in 2015 and is based in San Francisco, California.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The Company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. Jonathan M. Rothberg, Nevada Sanchez, and Tyler S. Ralston founded it in 2011, with its headquarters in Guilford in Connecticut.

Moxe Health Corporation develops a clinical data clearinghouse that enables the efficient bi-directional exchange of clinical, analytic, and administrative data among health systems, health plans, and healthcare technology vendors. The company offers solutions that automate chart retrieval and the release of information, transitioning health systems from manual processes to a fully electronic, auditable method of record management. Moxe’s platform facilitates access to essential data for risk adjustment, quality improvement, and care management programs, supporting health plans and providers in the shift to value-based care. Through its Substrate integration platform and Convergence framework, Moxe ensures that relevant patient information is integrated directly into clinician workflows within electronic medical records. Founded in 2012 and based in Madison, Wisconsin, Moxe Health aims to enhance the connectivity and functionality of existing healthcare data systems while maintaining compliance with HIPAA regulations.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer immunotherapies. Founded in 2017, the company is advancing a pipeline of therapeutic candidates designed to stimulate the immune system specifically within the tumor microenvironment. Utilizing its proprietary PREDATOR platform, Werewolf Therapeutics engineers conditionally activated molecules known as INDUKINE, which remain inactive in peripheral tissues but activate selectively in the presence of tumors. This targeted approach aims to enhance both adaptive and innate immune responses, addressing limitations associated with traditional proinflammatory therapies. Through its research and development efforts, Werewolf Therapeutics is committed to transforming cancer treatment.

SparingVision SAS is a biotechnology company based in Paris, France, focused on discovering and developing gene therapy-based treatments for blinding inherited retinal diseases. Founded in 2016, the company is working on SPVN06, a gene-independent therapy aimed at treating retinitis pigmentosa, the most common form of inherited retinal degeneration. This condition affects nearly 2 million people globally and currently lacks comprehensive treatment options for its various genetic forms. SparingVision’s efforts aim to provide innovative solutions for patients suffering from these debilitating diseases, enabling healthcare professionals to offer improved care for those at risk of blindness.

Cerevance LLC is engaged in the development of therapeutics targeting specific proteins expressed selectively in brain cell types affected by neurological diseases. The company utilizes its proprietary NETSseq platform to profile distinct brain cell types, such as neurons and glial cells, in mature human brain tissue. This technology reveals transcriptional and epigenetic differences, facilitating the early detection and treatment of serious neurological and psychiatric disorders, including Alzheimer’s and Parkinson’s diseases. Founded in 2016, Cerevance is headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom. The company's focus is on advancing new medicines for central nervous system diseases by addressing the underlying mechanisms of neurodegeneration and related conditions.